Enterprise Value
685.7B
Cash
1.997B
Avg Qtr Burn
-163.4M
Short % of Float
0.05%
Insider Ownership
0.00%
Institutional Own.
54.50%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VYVGART Hytrulo (SC Efgartigimod) Details MYASTHENIA GRAVIS, Autoimmune disease | Approved Quarterly sales | |
Efgartigimod Details Mucosal Pemphigus Vulgaris | Phase 3 Data readout | |
Efgartigimod Details Primary immune thrombocytopenia | Phase 3 Data readout | |
Efgartigimod Details Chronic inflammatory disorder | Phase 3 Update | |
Empasiprubart Details Neuropathy, Neuromuscular disease, Multifocal motorneuropathy | Phase 2 Data readout | |
Efgartigimod Details Sjögren-Larsson Syndrome | Phase 2 Data readout | |
Efgartigimod Details Post-COVID Postural Orthostatic Tachycardia Syndrome | Phase 2 Data readout | |
Empasiprubart Details Delayed graft function | Phase 2 Initiation |